Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

NCT05650164 · clinicaltrials.gov ↗
COMPLETED
Status
171
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany